Regulatory Relief To Promote Domestic Production of Critical Medicines
Headline: Directs Agencies to Streamline Domestic Drug Manufacturing Rules
What it does: Agencies must review and update regulations and permitting processes to speed and simplify domestic pharmaceutical manufacturing.
- Speeds and simplifies permits and approvals for U.S. drug plant construction and expansion.
- Increases fees and public reporting of inspections for foreign drug manufacturers.
- Clarifies rules to make moving production from overseas to U.S. facilities easier.
Summary
This order directs federal agencies to simplify and speed up rules, inspections, and permits that apply to making medicines in the United States. It focuses on removing duplicate requirements and making reviews more predictable so companies will build and expand drug factories domestically.
It asks the Food and Drug Administration, the Environmental Protection Agency, and the Army Corps to review and change regulations, provide clearer guidance for shifting production from overseas to U.S. plants, and improve inspection reporting and fees for foreign facilities to restore domestic production for American patients.
Ask about this order
Ask questions about this executive order and its implications.
What agencies are affected by this order?
How does this order change existing policy?
What are the practical implications of this order?